|CUSIP NO. 03217L106
||Page 10 of 14 Pages
Amryt Pharma plc (the “Issuer”)
Item 1(b). Address of Issuer’s Principal Executive
Dept 920a 196 High Road, Wood Green,
London, United Kingdom, N22 8HH
Name of Person
This statement (this “Statement”) is filed by the following
persons (the “Reporting Persons”):
Athyrium Opportunities II Acquisition 2 LP (“AOII Acquisition 2
Athyrium Opportunities III Acquisition 2 LP (“AOIII Acquisition
2 LP” and, together with AOII Acquisition 2 LP, the
“Acquisition 2 Funds”)
Athyrium Opportunities Associates II LP (“Associates II
Athyrium GP Holdings LLC (“GP Holdings”)
Athyrium Funds GP Holdings LLC (“Funds GP Holdings”)
Athyrium Opportunities Associates III LP (“Associates III
Athyrium Opportunities Associates III GP LLC (“Associates III
Jeffrey Ferrell (“Mr. Ferrell”)
Pursuant to Rule 13d-1(k)
promulgated under the Securities Exchange Act of 1934, as amended,
the Reporting Persons have entered into an agreement with respect
to the joint filing of this Statement, which agreement is set forth
on the signature page to this Statement.
Principal Business Office or, if none, Residence:
The principal business office address for each of the Reporting
Persons is: c/o Athyrium Capital Management, LP, 505 Fifth Avenue,
Floor 18, New York, New York 10017
The Acquisition 2 Funds, Associates II LP, and Associates III LP
are Delaware limited partnerships.
GP Holdings, Funds GP Holdings and Associates III GP are Delaware
limited liability companies.
Mr. Ferrell is a United States citizen.
Class of Securities:
Ordinary Shares, nominal value £0.06 per share, of the Issuer (the
As of the date of this Schedule 13G/A, a CUSIP number
for the Issuer’s Ordinary Shares is not available. The CUSIP number
for the Issuer’s American Depositary Shares, as previously reported
on this Schedule 13G, was 03217L106.